Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 269 participants.

Also called NCT02589639

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 269 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02589639
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02589639. Randomized; no masking; primary purpose treatment. Start 2015-10-28 (actual); primary completion 2017-04-18 (actual). Results posted on 2019-03-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Empagliflozin
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct02589639
Content hash
9ceb7e7a9732aa45681ccfb35ba464424fde8e75f2a316ddf785b2e90196d957